BioCentury
ARTICLE | Company News

Abide Therapeutics, Celgene deal

October 3, 2016 7:00 AM UTC

Celgene exercised an option from a 2014 deal and will obtain worldwide rights outside the U.S. to Abide’s ABX-1431. The product is in Phase Ia testing, and Abide plans to conduct additional Phase Ib ...